Game-Changing Specialty Diagnostic Technology

Multiple Sclerosis | IBS vs IBD | Fibromyalgia

The Science

Diagnose Faster

Across many autoimmune diseases, reaching a diagnosis can be a complicated journey spanning months to years. Our research shows that our Isolate tests will significantly shorten that timeline.

Treat Sooner

Treatments for autoimmune diseases are highly effective in reducing long term damage. The IQIsolate process identifies disease at the earliest onset of symptoms allowing for early treatment.

Improve Lives

Detecting disease early, implementing appropriate treatment plans at the right time and effectively managing chronic autoimmune conditions offers patients the opportunity to get back to living life.

IQuity's Breakthrough Autoimmune Technology

IQIsolate is a process utilizing machine learning methods to develop a suite of algorithms that analyze expression of RNA markers detected in a simple blood sample. IQuity has developed RNA-based diagnostic tests for autoimmune disease and related disorders in neurology, gastroenterology and rheumatology, three specialties that serve a majority of autoimmune patients.

Using the IQIsolate process, we analyze RNA expression data from a blood sample to identify the presence or absence of disease at the cellular level. RNA expression is representative of presence of disease in real time, while changes in DNA indicate potential risk of disease. The Isolate tests can distinguish among diseases in a given specialty – the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Within IBD, this test can accurately distinguish Crohn’s from ulcerative colitis. The IQIsolate process takes one week and delivers results with greater than 90% accuracy.

IQuity is firmly committed to data transparency and scientific peer review and will perform its tests in its independent CLIA certified lab in Nashville, TN.

“RNA-based diagnostics have the capability of providing highly accurate information that improves patient stratification. Measurements of RNA allow us to uncover a snapshot of gene activity in real time. This enables us to identify disease earlier than ever before. It is generally accepted that patients who get the right treatment sooner have improved long-term outcomes.”

Dr. Tom Aune, Co-Founder

Autoimmune Disease

There are over 80 different autoimmune diseases affecting 50 million Americans. Most are hard to diagnose, leaving patients waiting for answers for months to years while their organ systems are irreparably damaged. The current conventional methods for diagnosis at the earliest stages of disease are inconsistent and costly, involving repeated diagnostic testing and multiple provider visits. Conventional testing methods struggle to offer a yes or no; and, a negative result is as impactful as a positive result because it allows providers to focus on other diseases that explain patient symptoms.

IQuity's Isolate tests deliver a highly accurate result at the earliest sign of symptoms giving peace of mind to both patients and providers. 

Our Research

The IQIsolate algorithms were built on more than 2,500 patient samples from around the globe. Using machine learning methods, researchers were able to distinguish specific autoimmune diseases and related conditions among these enrolled subjects:

  • Healthy control subjects
  • Patients prior to diagnosis who are then followed in the EMR
  • Patients with disease prior to treatment
  • Patients with established disease
  • Disease controls spanning neurologic, gastrointestinal and rheumatologic disorders
2,500 patients recruited across multiple branches of medicine. Samples from healthy subjects and patients with disease were used for the studies.


DNA vs. RNA – Which Holds the Key to Early Disease Diagnosis?

Did you know that genes express themselves in different ways? They do - and they tell a story of an individual’s health and proclivity toward disease.

Learn More »